Advancements in Hormone Receptor-Positive Metastatic Breast Cancer

home / expertconnections / advancements-in-hormone-receptor-positive-metastatic-breast-cancer

Virginia Kaklamani, MD, DSc; and Megan Kruse, MD, discuss how advances in hormone receptor-positive metastatic breast cancer treatment, including ESR1 mutation testing and elacestrant therapy, help physicians optimize patient care and improve outcomes through personalized treatment selection.

Understanding Cancer Changes and Testing: How Testing Guides Your Metastatic Breast Cancer Treatment

EP. 1: Understanding Cancer Changes and Testing: How Testing Guides Your Metastatic Breast Cancer Treatment

Virginia Kaklamani, MD, DSc;Megan Kruse, MD
June 2nd 2025

Panelists discuss how testing for specific changes in cancer cells, like ESR1 mutations, can help guide treatment choices for patients with hormone receptor-positive metastatic breast cancer.

Navigating Treatment After Progression: Testing, ESR1 Mutations and Tolerable Options

EP. 2: Navigating Treatment After Progression: Testing, ESR1 Mutations and Tolerable Options

Virginia Kaklamani, MD, DSc;Megan Kruse, MD
June 2nd 2025

Panelists discuss how to approach second-line therapy decisions for patients with metastatic breast cancer, emphasizing the importance of biomarker testing, including ESR1 mutations, and considering patient-specific factors.

Exploring a Patient Case: Biomarker Testing After Progression and Discussing Treatment Choices With Your Care Team

EP. 3: Exploring a Patient Case: Biomarker Testing After Progression and Discussing Treatment Choices With Your Care Team

Virginia Kaklamani, MD, DSc;Megan Kruse, MD
June 2nd 2025

Panelists discuss how to communicate genomic testing results to patients and make shared treatment decisions, particularly when multiple targeted therapy options are available for patients with ESR1 and PIK3CA mutations.

EMERALD Trial Results: What Prior CDK4/6i Duration Means for Treatment Success

EP. 4: EMERALD Trial Results: What Prior CDK4/6i Duration Means for Treatment Success

Virginia Kaklamani, MD, DSc;Megan Kruse, MD
June 2nd 2025

Panelists discuss how the EMERALD trial demonstrated elacestrant's efficacy in ESR1-mutated tumors, particularly in patients who had received CDK4/6 inhibitors for at least 12 months. This led to its FDA approval for this specific population.

Managing Elacestrant Treatment: From Patient Selection to Supportive Care

EP. 5: Managing Elacestrant Treatment: From Patient Selection to Supportive Care

Virginia Kaklamani, MD, DSc;Megan Kruse, MD
June 2nd 2025

Panelists discuss balancing clinical trial data with real-world patient factors when choosing between treatment options, emphasizing the importance of quality of life alongside cancer control in the second-line setting.

Real-World Experience: The Efficacy and Tolerability of Oral Elacestrant for Patients with ESR1 Mutations

EP. 6: Real-World Experience: The Efficacy and Tolerability of Oral Elacestrant for Patients with ESR1 Mutations

Virginia Kaklamani, MD, DSc;Megan Kruse, MD
June 2nd 2025

Panelists discuss how real-world studies have shown improved outcomes with elacestrant compared with the original EMERALD trial data, demonstrating that proper patient selection leads to better treatment responses.

Patient Education, Shared Decision-Making, and Optimizing Care for ESR1-Mutated Breast Cancer

EP. 7: Patient Education, Shared Decision-Making, and Optimizing Care for ESR1-Mutated Breast Cancer

Virginia Kaklamani, MD, DSc;Megan Kruse, MD
June 2nd 2025

Panelists discuss how a multidisciplinary team approach to patient education and medication management is crucial for ensuring adherence and optimal outcomes with oral medications like elacestrant.